% | $
Quotes you view appear here for quick access.

Navidea Biopharmaceuticals, Inc Message Board

  • moneyonomics moneyonomics May 6, 2013 2:13 PM Flag

    Outside view- "if Navidea can generate sales before running out of capital, the stock could be a big winner."

    Whether you agree or not possibly some of the thinking and reason institutional buyers still on the sidelines

    ""Navidea...However, in the past three months Navidea stock dropped over 6%. The reason has probably more to do with the company's financials than the product. Revenues for 2012 were $79,000, a considerable drop compared to $598,000 for 2011. But the real issue appears to be the sustainability of the company, as it has roughly $11 million in cash, and in 2012 the company burned through $28.1 million. So the concern is: Will Navidea run out of capital before the products can bring in revenue to sustain the company? Brent Larson, Navidea's Senior Vice President and CFO, did address the financial concerns, "Through flexible access to multiple available funding sources, we have maintained a strong financial position in advance of expected revenue from our first radiopharmaceutical product, Lymphoseek. We believe that our cash flow and available financial resources are sufficient to support the ongoing advances in our pipeline programs and operating needs for the foreseeable future." The company has a $50 million equity line from Platinum-Montaur Life Sciences, and is confident that they will be able to secure a European partner for Lymphoseek, which could add an additional $10 million in working capital. .."

    Go to the "regular" investorvillage navb board to read more and get article site

1.51+0.01(+0.67%)Dec 1 4:02 PMEST